Background: Takotsubo Cardiomyopathy (TTC) is a reversible cardiomyopathy which is precipitated by adrenergic stress. Trigerring factors, clinical features and mortality data from Indian subcontinent is absent. Aims: The present study was undertaken to determine the clinical features, type of emotional stress, mode of presentation, duration of improvement, cardiogenic shock, in hospital mortality,and the treatment given to the patients. Methodology: This is a single centre retrospective study,done on patients who presented with ACS and 2D Echocardiography showing Regional Wall Motion Abnormality (RWMA) from 2010 to 2015. The confirmation of TTC was based on 2D Echo findings and coronary angio graphy(CAG). Statistical analysis used-Chi square test was used to compare the categorical variables between different stresses. Fisher exact test was also used to compare the categorical variables. We used independent t test to compare the mean of the ejection fraction between 2 groups. Results: Among 43 patients with TTC, most were females, between age group 51 to 80 yrs (77%). Most patients were found to have stress, in form of medical stress(35%), emotional stress(33%) with equal percentage. Some patients had surgical stress(21%) and some patients(11%) did not have any stress at all. In the present study 56 % had hypertension (HTN), 44% had Diabetes Mellitus (DM), and 9% had dyslipidemia (DLP). ECG showed T wave inversion(54%), ST elevation(49%), Q wave(9%), ST depression(7%) and no ST-T changes(5%). Initial Echo showed Ejection Fraction (EF) ≤ 35% in 46.5 %, 36-45% in 46.5 % and 46-55% in 7 %. Cardiogenic shock (18.6%) occurred frequently in surgical group and associated with high mortality. In our study EF improved in most of the patients(86%) within 1 month of follow up. Conclusions: TTC, predominantly involves females and is precipitated by medical illness or emotional stress in most of the patients. Recovery of left ventricular function is complete in all patients and prognosis is good. But when it occurs in patients following major non cardiac surgery, there can be significant mortality and morbidity.
Context: The assessment of left ventricular ejection fraction (LVEF) is the most important component in prediction and detection of cardiotoxicity in patients undergoing cancer chemotherapy. LVEF may not be sensitive enough to pick the cardiotoxicity early since drop in LVEF occurs in the last and irreversible stage. A 10%–15% early reduction in global longitudinal strain (GLS) by speckle tracking echocardiography proposed to be the earliest indicator of myocardial dysfunction. Aims: The aim of this study was to compare the early detection of cardiotoxicity (at 0 and 3 months) using drop in LVEF with two-dimensional echocardiography (2DE), three-dimensional echocardiography (3DE), and GLS techniques. Settings and Design: This was a prospective cohort study of patients attending cardiooncology clinic in a tertiary care institute. Subjects and Methods: Newly diagnosed 75 cases of cancer of various etiologies, for whom cardiotoxic chemotherapy drugs has to be used, were included from January 2016 to June 2016. Statistical Analysis Used: Data were analyzed with Pearson’s Chi-square test, mean, standard deviation, and 95% confidence interval. Results: A total of 17 (22.6%) subjects out of 75, had drop in LVEF by GLS (<−18.9%) as compared to 5 (6.6%) in 2DE and 7 (9.3%) in 3DE at 3 months with statistically significant P values ( P = 0.0001). In the 17 subjects who had significant fall in GLS at 3 months, the mean GLS was −16.17 ± 1.55% with a significant reduction of 13.48% from baseline. Conclusion: Reduction in GLS preceded decrease in ejection fraction. Early detection allows modification of chemotherapeutic regimens and medical intervention preventing the irreversible cardiac damage.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2025 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.